PMID: 2107780Apr 1, 1990Paper

Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial

Annals of Internal Medicine
L J RubinW Long

Abstract

To determine the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary pulmonary hypertension. Randomized trial with 8-week treatment periods and nonrandomized treatment for up to 18 months. Four referral centers. Sequential sample of 24 patients with primary pulmonary hypertension. Nineteen patients completed the study. Four patients died and one left the study because of adverse effects (pulmonary edema). Continuous intravenous prostacyclin administered by portable infusion pump at doses determined by acute responses during baseline catheterization in ten patients. Nine patients were treated with anticoagulants, oral vasodilators, and diuretics. Starting with a baseline value for total pulmonary resistance of 21.6 units, there was a decrease of 7.9 units (95% CI, -13.1 to -2.2; P = 0.022) in the prostacyclin-treated group after 8 weeks; there was virtually no change in the conventional therapy group (from 20.6 to 20.4 units, not significant). Six of ten prostacyclin-treated patients who completed the 8-week study period had reductions in mean pulmonary artery pressure of greater than 10 mm Hg, whereas only one of nine in the conventional treatment group had a similar response (P = 0.057). Nine ...Continue Reading

Citations

Mar 1, 1995·European Journal of Pediatrics·B SantakP Radermacher
Nov 7, 2002·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Kassiani TheodorakiTheophani Antoniou
Sep 13, 2013·European Journal of Clinical Pharmacology·Yaguo ZhengChangming Xiong
Mar 29, 2005·Zeitschrift für Rheumatologie·G Riemekasten, H Schulze-Koops
Aug 19, 2011·General Thoracic and Cardiovascular Surgery·Kengo F Kusano
Aug 31, 2001·Current Treatment Options in Cardiovascular Medicine·Andrew J. Maxwell, Nancy D. Bridges
Apr 2, 2011·Advances in Therapy·Jean-Luc Vachiéry
Dec 1, 1991·Journal of the American College of Cardiology·J RhodesW M Gersony
May 18, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Friedrich M FruhwaldWerner Klein
Jan 19, 1995·The American Journal of Cardiology·J H PattersonR A McKinnis
Jan 19, 1995·The American Journal of Cardiology·G A HaywoodW J McKenna
Jan 19, 1995·The American Journal of Cardiology·L J Rubin
Jan 19, 1995·The American Journal of Cardiology·N GalièB Magnani
Jan 19, 1995·The American Journal of Cardiology·S Rich
Jan 19, 1995·The American Journal of Cardiology·G Cremona, T Higenbottam
Apr 24, 1999·Obstetrics and Gynecology·T R EasterlingB C Schmucker
Sep 5, 1998·Lancet·S P Gaine, L J Rubin
Jan 1, 1997·Ryōikibetsu shōkōgun shirīzu·H Ohtani, H Imai
Oct 10, 2001·Clinics in Chest Medicine·A P Fishman
Aug 1, 1997·Journal of the American College of Cardiology·S M ShapiroB H Brundage
Oct 16, 1999·Journal of the American College of Cardiology·N NagayaT Kunieda
Aug 26, 2006·Nature Clinical Practice. Rheumatology·Marc Humbert, Gérald Simonneau
Jul 20, 2011·Nature Reviews. Cardiology·Dermot S O'CallaghanMarc Humbert
Feb 1, 1996·The New England Journal of Medicine·R J BarstUNKNOWN Primary Pulmonary Hypertension Study Group
May 30, 1996·The New England Journal of Medicine·T Higenbottam
Jan 9, 1997·The New England Journal of Medicine·L J Rubin
Oct 2, 2004·The New England Journal of Medicine·Marc HumbertGérald Simonneau
Aug 20, 2002·Journal of Aerosol Medicine : the Official Journal of the International Society for Aerosols in Medicine·Tobias GesslerWerner Seeger
Jun 4, 2008·Journal of Aerosol Medicine and Pulmonary Drug Delivery·Tobias GesslerThomas Schmehl
Jan 22, 2009·European Heart Journal·Nazzareno GalièAngelo Branzi
Mar 31, 1998·The American Journal of the Medical Sciences·S P Gaine, L J Rubin
Nov 7, 1999·Current Opinion in Rheumatology·C P MeloneS Beldner
Nov 1, 2002·Current Opinion in Rheumatology·John Varga
Feb 7, 2001·Critical Care Medicine·R N Channick, L J Rubin
Mar 26, 1998·Journal of Cardiovascular Pharmacology·A SaadjianS Levy

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.